As the evidence is weaker when it comes to the patient population with asymptomatic HFpEF and an eGFR < 60 mL/min/1.73 m2, there is a need to discover an effective tool to predict positive cardiac function responses when administering SGLT2 inhibitors to individuals with symptomatic HF. This evidence concerns the gene SLC5A2 and hydrops fetalis.